Thrombosis最新文献_第5页

The role of dermcidin isoform 2: a two-faceted atherosclerotic risk factor for coronary artery disease and the effect of acetyl salicylic Acid on it. 去皮素异构体2的作用:冠状动脉疾病的双重动脉粥样硬化危险因素及乙酰水杨酸的影响

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-02-06 DOI: 10.1155/2012/987932

Rajeshwary Ghosh, Uttam K Maji, Rabindra Bhattacharya, Asru K Sinha

{"title":"The role of dermcidin isoform 2: a two-faceted atherosclerotic risk factor for coronary artery disease and the effect of acetyl salicylic Acid on it.","authors":"Rajeshwary Ghosh, Uttam K Maji, Rabindra Bhattacharya, Asru K Sinha","doi":"10.1155/2012/987932","DOIUrl":"https://doi.org/10.1155/2012/987932","url":null,"abstract":"Hypertension and diabetes mellitus are considered to be two major atherosclerotic risk factors for coronary artery disease (CAD). A stress-induced protein identified to be dermcidin isoform 2 of Mr. 11 kDa from blood plasma of hypertensive persons when injected (0.1 μM) in rabbits increased the systolic pressure by 77% and diastolic pressure by 45% over the controls within 2 h. Ingestion of acetyl salicylic acid (150 mg/70 kg) by these subjects reduced systolic (130 mm Hg) and diastolic pressures (80 mm Hg) with reduction of plasma dermcidin level to normal ranges (9 nM). The protein was found to be a potent activator of platelet cyclooxygenase and inhibited insulin synthesis. Aspirin was found to reduce hypertension by reduction of plasma dermcidin level, neutralized the effect of cyclooxygenase, and restored the pancreatic insulin synthesis through NO synthesis. These results indicated that dermcidin could be a novel atherosclerotic risk factor for its hypertensive and diabetogenic effects.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"987932"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/987932","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30529531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Paradoxical effect of aspirin. 阿司匹林的矛盾效应

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-01-15 DOI: 10.1155/2012/676237

Christian Doutremepuich, Omar Aguejouf, Vanessa Desplat, Francisco X Eizayaga

{"title":"Paradoxical effect of aspirin.","authors":"Christian Doutremepuich, Omar Aguejouf, Vanessa Desplat, Francisco X Eizayaga","doi":"10.1155/2012/676237","DOIUrl":"10.1155/2012/676237","url":null,"abstract":"Low-dose aspirin is an important therapeutic option in the secondary prevention of myocardial infarction (MI) and ischemic stroke, basedon its unique cost-effectiveness and widespread availability. In addition, based on the results of a number of large studies, aspirin is also widely used in the primary prevention of MI. This paper provides an update of the available data to offer greater clarity regarding the risks of aspirin with respect to hemorrhagic stroke. In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage. When considering whether aspirin is appropriate, the absolute therapeutic cardiovascular benefits of aspirin must be balanced with the possible risks associated with its use, being hemorrhagic stroke. Regarding these clinical facts, normal, COX 1 -/-, and COX 2 -/- mice were treated with a wide range of doses of aspirin and studied by induced hemorrhagic time. The results outlined three major conclusions: high doses of aspirin induce hemorrhage, while low doses of aspirin do not. In the absence of COX 1, ultra low doses of aspirin produce an antihemorrhagic effect not observed with intermediate doses. The absence of COX 2 induced a hemorrhagic effect that needs further research, probably originated in compensatory phenomena.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"676237"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30424916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lack of Association between Recurrent Pregnancy Loss and Inherited Thrombophilia in a Group of Colombian Patients. 在一组哥伦比亚患者中，反复流产与遗传性血栓形成缺乏关联。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-04-11 DOI: 10.1155/2012/367823

Henry Cardona, Serguei A Castañeda, Wálter Cardona Maya, Leonor Alvarez, Joaquín Gómez, Jorge Gómez, José Torres, Luis Tobón, Gabriel Bedoya, Angela P Cadavid

{"title":"Lack of Association between Recurrent Pregnancy Loss and Inherited Thrombophilia in a Group of Colombian Patients.","authors":"Henry Cardona, Serguei A Castañeda, Wálter Cardona Maya, Leonor Alvarez, Joaquín Gómez, Jorge Gómez, José Torres, Luis Tobón, Gabriel Bedoya, Angela P Cadavid","doi":"10.1155/2012/367823","DOIUrl":"https://doi.org/10.1155/2012/367823","url":null,"abstract":"Studies have shown an association between recurrent pregnancy loss and inherited thrombophilia in Caucasian populations, but there is insufficient knowledge concerning triethnic populations such as the Colombian. The aim of this study was to evaluate whether inherited thrombophilia is associated with recurrent pregnancy loss. Methods. We conducted a case-control study of 93 patients with recurrent pregnancy loss (cases) and 206 healthy multiparous women (controls) in a Colombian subpopulation. Three single nucleotide polymorphisms (SNPs) markers of the inherited thrombophilias factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T were genotyped by PCR-RFLP. Activated protein C resistance and plasma levels of antithrombin, protein C, and protein S were also measured. Results. The frequency of thrombophilia-associated SNPs, activated protein C resistance, and anticoagulant protein deficiencies, was low overall, except for the methylenetetrahydrofolate reductase C677T SNP. The differences between patients and controls had no statistical significance. Conclusion. Our study confirms the low prevalence of inherited thrombophilias in non-Caucasian populations and it is unlikely that the tested thrombophilias play a role in the pathogenesis of recurrent pregnancy loss in this Colombian population.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"367823"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/367823","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30610562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Are we missing post-thrombotic syndrome syndrome? An orthopaedic perspective in lower limb arthroplasty. 我们是否遗漏了血栓后综合征？从骨科角度看下肢关节置换术。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2011-10-27 DOI: 10.1155/2012/324320

M Reidy, A Macinnes, A Pillai

引用次数: 0

Beneficial effect of ultra-low-dose aspirin in platelet activity alterations and haemorrhage observed in experimental portal hypertension. 超低剂量阿司匹林对实验性门静脉高压症血小板活性改变和出血的有益作用。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2011-11-14 DOI: 10.1155/2012/430460

F X Eizayaga, O Aguejouf, V Desplat, C Doutremepuich

引用次数: 4

The role of anticoagulation clinics in the era of new oral anticoagulants. 临床抗凝作用的新时代口服抗凝剂。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-10-14 DOI: 10.1155/2012/835356

Sophie Testa, Oriana Paoletti, Anke Zimmermann, Laura Bassi, Silvia Zambelli, Emilia Cancellieri

{"title":"The role of anticoagulation clinics in the era of new oral anticoagulants.","authors":"Sophie Testa, Oriana Paoletti, Anke Zimmermann, Laura Bassi, Silvia Zambelli, Emilia Cancellieri","doi":"10.1155/2012/835356","DOIUrl":"https://doi.org/10.1155/2012/835356","url":null,"abstract":"Anticoagulation Clinics (ACs) are services specialized in management of patients on anticoagulant treatment. At present, ACs manage patients chiefly on antivitamin K antagonists (AVKs), but patient population has already changed in the last few years, because of an increase of treatments with other anticoagulant drugs, which require different management systems. The strong increase in the number of patients at AC, mainly on long-term treatment, has determined the development of web management, through telemedicine systems, improving the quality of life and maintaining the same clinical quality levels. New oral anticoagulants (NOAs) have shown to be as effective as AVK antagonists in stroke prevention in atrial fibrillation and for treatment of venous thromboembolism in addition to VTE prophylaxis in orthopaedic surgery, when administered at a fixed dose, but patient adherence and compliance are crucial for good quality treatment. At present, lacking data from the real world, an oversimplification of treatment with NOAs could cause unjustified risks for patients and also a possible future underuse of good drugs. For these reasons the vigilance must be high and ACs can have a crucial role in defining which is the best management for NOA patients and how to do it, as it happened for AVKs.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"835356"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/835356","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31002151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 32

Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients? 阿司匹林和其他抗血小板药物能降低危重病人的死亡率吗?

Thrombosis Pub Date : 2012-01-01 Epub Date: 2011-11-09 DOI: 10.1155/2012/720254

Wolfgang Lösche, Janina Boettel, Björn Kabisch, Johannes Winning, Ralf A Claus, Michael Bauer

引用次数: 58

Anti-phospholipid antibodies in patients undergoing total joint replacement surgery. 全关节置换术患者的抗磷脂抗体。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-10-31 DOI: 10.1155/2012/142615

Melissa Simpson, Michael J Sanfelippo, Adedayo A Onitilo, James K Burmester, William Hocking, Steven H Yale, Joseph J Mazza

{"title":"Anti-phospholipid antibodies in patients undergoing total joint replacement surgery.","authors":"Melissa Simpson, Michael J Sanfelippo, Adedayo A Onitilo, James K Burmester, William Hocking, Steven H Yale, Joseph J Mazza","doi":"10.1155/2012/142615","DOIUrl":"https://doi.org/10.1155/2012/142615","url":null,"abstract":"Background. Patients undergoing joint replacement remain at increased risk for venous thromboembolism (VTE) compared to other types of surgery, regardless of thromboprophylactic regimen. The pathophysiologic processes rendering this group of patients at risk for VTE are multifactorial. Procedure-specific and patient-specific exposures play a role in the postoperative development of VTE, including the development of anti-phospholipid antibodies (aPL). Methods. We measured three aPL (anti-cardiolipin, anti-β(2) glycoprotein, and lupus anticoagulant) in 123 subjects undergoing total knee or hip arthroplasty to describe the presence of these antibodies preoperatively and to describe the rate of postoperative seroconversion among those people who were negative preoperatively. Postoperative antibodies were measured at day 7, 14, and 21. Results. The prevalence of aPL antibodies in the preoperative period was 44%, positive subjects were more likely to be smokers (P = 0.05) and were less likely to have undergone a previous arthroplasty procedure (P = 0.002). Subjects seroconverted in a 21 day postoperative period at a rate of 79%. Conclusions. These pilot data suggest that the prevalence of aPL in this population both preoperatively and postoperatively is higher than previously expected. Further studies are needed to describe aPL in a larger population and to establish their clinical significance in populations undergoing joint replacement surgeries.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"142615"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/142615","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31101366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement. 第一代药物洗脱支架置入后晚期和极晚期支架血栓形成的病理病因。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2012-11-21 DOI: 10.1155/2012/608593

Fumiyuki Otsuka, Masataka Nakano, Elena Ladich, Frank D Kolodgie, Renu Virmani

{"title":"Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement.","authors":"Fumiyuki Otsuka, Masataka Nakano, Elena Ladich, Frank D Kolodgie, Renu Virmani","doi":"10.1155/2012/608593","DOIUrl":"https://doi.org/10.1155/2012/608593","url":null,"abstract":"Several randomized and observational studies have reported steady increase in cumulative incidence of late and very late ST (LST/VLST) following first-generation drug-eluting stents (DES: sirolimus-(SES) and paclitaxel-(PES)) up to 5 years. Pathologic studies have identified uncovered struts as the primary substrate responsible for LST/VLST following DES, where delayed arterial healing is associated with stent struts penetrating into the necrotic core, long/overlapping stents, and bifurcation stenting especially in flow divider region. Grade V stent fracture also induces LST/VLST and restenosis. Hypersensitivity reaction is exclusive to SES as an etiology of LST/VLST, whereas malapposition secondary to excessive fibrin deposition is associated with PES. Uncovered struts can be identified in SES and PES with duration of implant beyond 12 months, particularly in stents placed for \"off-label\" indications. Neoatherosclerosis is another important contributing factor for VLST in DES and bare metal stents (BMS); however, DES shows rapid and more frequent development of neoatherosclerosis than BMS. Future pathologic studies should address the long-term safety of newer generation DES including zotarolimus- and everolimus-eluting stents in terms of the improvement in reendothelialization, decreased inflammation and fibrin deposition as well as a lower incidence of stent fracture-related adverse events, and reduced neoatherosclerosis, which likely contribute to the decreased risk of LST/VLST and better patient outcomes.","PeriodicalId":75222,"journal":{"name":"Thrombosis","volume":"2012 ","pages":"608593"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/608593","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31113256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 64

Aspirin: pharmacology and clinical applications. 阿司匹林:药理学和临床应用。

Thrombosis Pub Date : 2012-01-01 Epub Date: 2011-11-17 DOI: 10.1155/2012/173124

Enma V Paez Espinosa, John P Murad, Fadi T Khasawneh

引用次数: 59